Application of Quadrivalent Influenza Vaccine (QIV)
From the end of 2017 to the beginning of 2018, the epidemic situation of influenza in China was serious. According to the data of Chinese Center for Disease Control and Prevention, the proportion of influenza-like cases in emergency departments and positive rate of influenza virus detection reported by hospitals in influenza monitoring posts in China were higher than that of the same period in the past three years. The number of influenza outbreaks reported in China was significantly higher than that of the same period in previous years. The number of confirmed cases and severe cases of influenza also increased, while the predominant virus in epidemic was Yamagata strain type B (By).
According to the recommended components of 2018 - 2019 seasonal influenza vaccine in the northern hemisphere released by the WHO on February 22, 2018, the Influenza Vaccine (Split, Virion), Quadrivalent contains four influenza virus antigen components, type A H1N1, type A H3N2, type B Yamagata (By) and type B Victoria (Bv), while the Influenza Vaccine (Split, Virion), Trivalent contains three influenza virus antigen components, type A H1N1, type A H3N2, type B Victoria (Bv), without type B Yamagata (By). The Quadrivalent Influenza Vaccine developed by the Hualan Bio this time contains the above two influenza A and two influenza B antigens, covering more influenza epidemic types, which will effectively prevent and control influenza epidemic.
TAG:  Quadrivalent Influenza Vaccine, Hualan Bio, Influenza Pandemic, Influenza Vaccine (Split, Virion), Quadrivalent